Postoperative adjuvant aspirin for patients with hepatitis B virus-related hepatocellular carcinoma and portal vein tumor thrombus: An open-label, randomized controlled trial

PurposeTo compare the survival outcomes of postoperative adjuvant aspirin with surgery alone in patients hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT).MethodsFrom June 2013 to July 2015, an open-label, randomized controlled study was conducted resectable HBV-related HCC PVTT. Patients were randomly assigned undergo surgical resection (n = 40) or hepatectomy 40). The primary end point overall (OS). secondary points time recurrence (t-TTR) PVTT (p-TTR). expression levels COX1 COX2 specimens group correlated patients’ survival.ResultsThe median OS t-TTR 16.2 13.4 months, 5.3 3.2 months for group, respectively. There no significant difference between two groups (P 0.078 0.336, respectively). p-TTR 12.0 5.4 had markedly longer 0.001). Increased expressions tissues denoted better prognosis receiving aspirin.ConclusionFor PVTT, significantly prolonged than alone. Expression may predict these patients.